Patents by Inventor Jonathan F. Head

Jonathan F. Head has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190167631
    Abstract: Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 6, 2019
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Publication number: 20190167788
    Abstract: Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 6, 2019
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Publication number: 20160317490
    Abstract: Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer.
    Type: Application
    Filed: May 2, 2016
    Publication date: November 3, 2016
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Publication number: 20160136269
    Abstract: Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.
    Type: Application
    Filed: November 16, 2015
    Publication date: May 19, 2016
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Patent number: 9333189
    Abstract: Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: May 10, 2016
    Assignee: ONCBIOMUNE, INC.
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Patent number: 9211322
    Abstract: Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 15, 2015
    Assignee: ONCBIOMUNE, INC.
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Publication number: 20140112884
    Abstract: Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 24, 2014
    Applicant: OncBioMune, L.L.C.
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Patent number: 8647627
    Abstract: Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: February 11, 2014
    Assignee: OncBioMune, L.L.C.
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Publication number: 20120282215
    Abstract: Pharmaceutical compositions containing (i) whole autologous cancer cells, whole allogeneic cancer cells, or a combination thereof; (ii) a colony stimulating factor (CSF); (iii) an interleukin; and (iv) a pharmaceutically acceptable carrier are described which are useful for inhibiting tumor growth, progression or recurrence or to inhibit metastases formation in solid cancerous tumors, leukemias, and lymphomas.
    Type: Application
    Filed: January 13, 2011
    Publication date: November 8, 2012
    Applicant: OncBioMune, L.L.C.
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Publication number: 20120282216
    Abstract: Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.
    Type: Application
    Filed: January 13, 2011
    Publication date: November 8, 2012
    Applicant: OncBioMune, L.L.C.
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Publication number: 20110190204
    Abstract: Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer.
    Type: Application
    Filed: January 31, 2011
    Publication date: August 4, 2011
    Applicant: ONCBIOMUNE, L.L.C.
    Inventors: Jonathan F. Head, Robert L. Elliott
  • Patent number: 5478556
    Abstract: A breast cancer vaccine which comprises a mixture of tumor associated antigens (TAA) with low doses of recombinant interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF).
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: December 26, 1995
    Inventors: Robert L. Elliott, Jonathan F. Head